electroCore Announces Second Quarter 2025 Financial Results

What was the earnings per share (EPS) for Q2 2025 and how does it compare to Q2 2024? Did the company meet or exceed consensus analyst expectations for revenue and EPS? Are there any updates on the company’s cash position, capital expenditures, or R&D spending for the quarter? Is there any guidance on future quarterly or FY2025 sales growth? What is the gross margin and operating margin for the quarter, and are there any notable changes? How might the results affect the short‑term technical outlook – potential breakout or pull‑back? Are there any risk factors or one‑off items disclosed that could affect future performance? What impact might the strong sales momentum have on the stock’s price‑to‑sales (P/S) multiple? What are the key drivers behind the sales acceleration – new product launches, geographic expansion, or contract wins? How does the 20% YoY sales increase compare to historical growth rates and to peers in the med‑tech sector? Could the higher sales translate into improved profitability, or is the company still operating at a loss? What is the company’s revised outlook for the remaining 2025 fiscal year, and does it include any adjustments to pricing or cost structure?